Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring, Detoxifying, and Rebalancing Metals During AML and MDS Therapy
NCT03630991Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2018
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of edetate calcium disodium and succimer in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML) and 1 more (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events, Maximum tolerated doses and 1 more. Started Oct 2018; status: recruiting.
02
Drugs
edetate calcium disodiumsuccimer
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT03630991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630991.